Longevity: what are the top startups now?

Last updated: 21 October 2026
Cover of NewMarketPitch's longevity report

Everything we know about the longevity market, in one place. Get our report whether you build or invest.

Summary

NewLimit is currently the leading longevity biotechnology startup, followed by Life Biosciences and Retro Biosciences. Altos Labs remains the industry's biggest long-term research bet, while Neko Health leads the commercial preventive-health market.

The longevity industry has split into two businesses with very different measures of success. Experimental biotechnology companies are trying to change how cells age, while preventive-health businesses are already generating revenue from diagnostics, screening, and continuous monitoring. Experimental biotech and preventive health get judged by different yardsticks, so we compare which business models are winning in our longevity market report.

NewLimit's rise is particularly striking. It raised $610 million across three financings in approximately thirteen months, reaching a $3.1 billion valuation while developing epigenetic reprogramming therapies that have yet to enter human trials.

Life Biosciences has achieved something its larger competitors haven't: treating human patients with a cellular-reprogramming therapy. Its first three glaucoma participants showed encouraging early safety observations, although preliminary improvements in vision remain far from proof of efficacy.

Retro Biosciences has also crossed into human testing, with its experimental autophagy drug RTR242. The contrast with NewLimit is interesting: Retro is pursuing several approaches to aging, while NewLimit is making a more concentrated bet on restoring cellular function through epigenetic reprogramming.

Altos Labs has approximately $3 billion in initial funding commitments, an extraordinary advantage in scientific talent and research capacity. Yet its publicly disclosed pipeline still lacks the human clinical milestones achieved by much smaller competitors. Financial strength and clinical leadership are clearly not the same thing.

The commercial side has developed much faster. Neko Health has served more than 100,000 customers and raised $700 million at a valuation approaching $7 billion. Function Health is building a laboratory-based membership platform, while Oura reported $908 million in fiscal 2025 revenue and around five million paid memberships by June 2026.

Loyal could deliver one of the industry's most important commercial milestones, although its first longevity medicines are being developed for dogs. Its veterinary regulatory strategy offers a potentially faster way to test whether a drug can extend healthy lifespan.

Cellular reprogramming currently has the strongest combination of scientific ambition, investment, and emerging clinical evidence. But success in restoring retinal function, improving liver cells, or treating one age-related disease would not automatically establish that a therapy slows aging throughout the human body.

The central scientific gap remains enormous: no leading startup has demonstrated that its treatment meaningfully extends human lifespan. Biological-age tests can help measure responses to interventions, but changes in those markers still cannot be treated as additional years of life.

Our ranking therefore favors observable progress over headline valuations. NewLimit leads on platform development and funding momentum, Life Biosciences on early human reprogramming evidence, and Neko Health on commercial execution. The next major shift in leadership will probably come from convincing clinical results rather than another record-breaking financing.

Written by the New Market Pitch teamWe track new markets so founders and investors can move faster. About us

Market grid of the top longevity startups and companies by segment: Who are the top companies in the longevity market? (Longevity Market, NewMarketPitch)

In our report covering the longevity market, we turn what is vague and complex into simple, useful visuals. Market maps like this one show you at a glance where every startup stands.

Which longevity startups are leading the field right now?

NewLimit, Life Biosciences, Retro Biosciences, and Altos Labs are currently the strongest contenders in longevity biotechnology, while Neko Health, Function Health, and Oura lead the commercial health-monitoring market.

The industry has split into two very different businesses. One is developing experimental therapies that could restore the function of aging cells, slow biological deterioration, or treat diseases associated with aging. The other sells preventive healthcare, biological measurements, and continuous monitoring to people who want to stay healthier for longer.

The difference has become harder to ignore as valuations have climbed. NewLimit raised $435 million in June 2026 at approximately a $3.1 billion valuation. Retro Biosciences announced financing at a $1.8 billion pre-money valuation. Meanwhile, Neko Health secured $700 million at a valuation approaching $7 billion, despite operating a completely different business from companies developing rejuvenation therapies.

We therefore see several legitimate leaders. NewLimit stands out for its research platform and progress toward clinical testing. Life Biosciences has already treated humans with an experimental cellular-reprogramming therapy. Neko Health has demonstrated substantial consumer demand. Altos Labs remains the industry's biggest long-term research bet.

What actually counts as a longevity startup?

Longevity startups fall into two main groups today: companies trying to change the biology of aging and companies helping people manage their health as they get older.

Altos Labs and NewLimit aim to restore healthier functions in aging cells. Life Biosciences investigates whether cellular reprogramming can repair damaged tissues. Retro Biosciences is developing several treatments targeting biological processes associated with aging.

Neko Health and Function Health approach longevity through earlier detection of health problems. Oura tracks sleep, activity, temperature, and other physiological measurements that can help people understand their health.

A diagnostic service can start charging customers immediately, while a company developing rejuvenation medicines may spend years running experiments and clinical trials before generating pharmaceutical revenue.

For our ranking, we include both categories but distinguish consumer adoption from scientific progress. We also focus on private companies, using listed businesses such as BioAge Labs and Insilico Medicine when they offer useful comparisons.

Is Altos Labs still the biggest longevity startup?

Altos Labs remains the most heavily capitalized pure longevity biotechnology startup, with approximately $3 billion in initial funding commitments, although it still trails some smaller competitors in publicly demonstrated clinical progress.

Launched in 2022 with backing associated with Jeff Bezos and other wealthy investors, Altos assembled major research operations focused on cellular reprogramming and resilience.

Its research has increasingly moved toward specific biological mechanisms. A 2025 study published in Cell examined mesenchymal drift, a process in which aging or diseased cells lose specialized characteristics and develop features associated with fibrosis. Researchers identified ways cellular reprogramming could reverse aspects of this process.

Altos also acquired Dorian Therapeutics in 2025, adding research involving senescence-related biology and small-molecule treatments.

However, Altos had not publicly disclosed a named clinical candidate or an Altos-sponsored human trial by September 2026. Life Biosciences had already started treating patients, and Retro Biosciences had advanced a drug into Phase 1.

We still consider Altos one of the most important longevity startups, but its leadership currently rests on scientific talent, research capabilities, and financial resources rather than demonstrated results in patients.

Comparison table of the tech offered by leading longevity companies: Which longevity player has the most complete tech today? (Longevity Market, NewMarketPitch)

Our research about longevity companies gets updated several times a month, so you always get the latest view of where things stand.

Has NewLimit become the most promising anti-aging biotech?

NewLimit is currently our strongest overall candidate for the leading longevity therapeutics startup because its research progress, financing, and plans for clinical trials are starting to come together.

Founded in 2021 by Brian Armstrong, Blake Byers, and Jacob Kimmel, NewLimit develops epigenetic reprogramming medicines intended to restore healthier functions in older cells without fully reverting them to stem cells.

The financing has accelerated sharply. NewLimit announced a $130 million Series B in May 2025, an additional $45 million in October, and a $435 million Series C in June 2026. NewLimit stacked three rounds in about a year, and we follow who has raised the most, and from whom, in our longevity market report.

That adds up to $610 million across three disclosed financings in approximately thirteen months. The latest round, led by Founders Fund, valued NewLimit at around $3.1 billion, according to CEO Jacob Kimmel's comments to STAT.

The company has also reported measurable scientific progress. Its July 2026 research update described four additional therapeutic leads that restored function in older liver cells, a 100-fold manufacturing scale-up for its lead asset, and improvements in the efficiency of its computational reprogramming system.

NewLimit expects to begin its first human clinical trial in 2027. The company has assembled an unusually strong combination of financing and preclinical progress, but still has to demonstrate that its treatments work in patients.

Is Retro Biosciences catching up with NewLimit?

Retro Biosciences is currently ahead of NewLimit in reaching human clinical trials, although NewLimit has attracted more recent disclosed funding and reached a higher valuation.

Founded in 2022 with substantial financial backing from Sam Altman, Retro has set itself an ambitious goal: extending healthy human lifespan by approximately ten years.

The company is pursuing several approaches, including enhancing autophagy, cellular reprogramming, cell replacement, and AI-assisted protein engineering.

Its clearest clinical milestone is RTR242, an oral experimental treatment intended to improve cellular protein clearance. Retro has advanced the drug into a Phase 1 study involving Alzheimer's disease.

In May 2026, Retro announced the initial close of another financing round at a $1.8 billion pre-money valuation. Its management also reported that RTR242 moved from indication selection to first-in-human dosing in approximately fifteen months.

The contrast with NewLimit is revealing. NewLimit is concentrating on epigenetic reprogramming, starting with liver cells, while Retro is building a broader collection of treatments targeting different aspects of aging.

We favor NewLimit's focused platform and funding trajectory for now, but Retro has already moved a longevity-related drug into human testing.

Which longevity startups have raised the most money?

Altos Labs, Oura, Neko Health, and NewLimit are among the best-funded private companies associated with longevity, but their funding reflects very different kinds of businesses.

Altos entered the market with approximately $3 billion in commitments. Oura has raised around $1.6 billion according to CB Insights, while Neko Health's latest financing brought its cumulative funding above $1 billion.

NewLimit's approximately $680 million in cumulative disclosed financing is smaller, but the pace of its fundraising is remarkable for a company still working toward its first clinical trial.

We also found a pronounced concentration of funding among experimental longevity companies. A New Market Pitch review of twelve longevity-focused businesses with disclosed financings beginning in 2025 identified approximately $950 million in announced funding. NewLimit accounted for $610 million, or around 64%. Adding Life Biosciences' $80 million Series D and Juvenescence's $76 million Series B-1 first close brings the three companies' combined share to about 81%.

That is a selected sample rather than a complete industry funding total, but it shows how unevenly investors are distributing capital.

On the consumer side, Neko Health raised $700 million in a single round in July 2026, exceeding NewLimit's latest $435 million financing. Neko can point to paying customers and operating clinics, while NewLimit's valuation depends on future drug development.

The figures below are approximate. Some include initial commitments, while others reflect cumulative disclosed or tracked financing.

Company Funding scale Main activity
Altos Labs ~$3.0B committed Cellular rejuvenation
Oura ~$1.6B raised Health-monitoring wearables
Neko Health ~$1.0B–$1.2B raised Preventive health scans
NewLimit ~$680M raised Epigenetic reprogramming
Function Health $500M+ tracked Preventive diagnostics
Retro Biosciences $180M+ initial backing; later amount undisclosed Longevity therapeutics
Loyal $100M Series C, plus earlier funding Canine longevity drugs
Life Biosciences $80M Series D, plus earlier funding Cellular reprogramming
Scorecard showing what sets the leading longevity company apart: Why is Function Health winning the longevity testing market? (Longevity Market, NewMarketPitch)

In our market report about longevity companies, we look at what the winners do differently, so you can learn from the best instead of guessing.

Has Life Biosciences actually reversed aging in humans?

Life Biosciences has now tested cellular reprogramming in human patients, making it one of the most scientifically important longevity startups, but there is still no proof that its treatment reverses human aging.

Its experimental therapy, ER-100, uses controlled expression of three reprogramming factors, OCT4, SOX2, and KLF4, to try to restore function in damaged retinal nerve cells.

The FDA cleared the investigational application in January 2026, and the first patient was dosed in June. The study focuses on serious eye conditions, including open-angle glaucoma and non-arteritic anterior ischemic optic neuropathy.

Life Biosciences reported its first human observations in October 2026. Three participants with glaucoma received the initial dose, and the treatment was reportedly well tolerated through Day 56.

Two participants also showed preliminary improvements in visual-field measurements. According to the company's published results, at least 28% of tested visual-field points in those two patients improved by more than four decibels.

The results are encouraging, although three participants in an open-label safety study cannot establish efficacy. Visual-field tests can vary, and we cannot yet separate potential treatment effects from other explanations.

Life Biosciences has nonetheless reached a stage that several much better-funded longevity competitors have yet to reach.

Is Neko Health the biggest commercial winner in longevity?

Neko Health is currently one of the clearest commercial winners in longevity-related healthcare, with more than 100,000 customers served and a valuation approaching $7 billion.

Co-founded by Spotify founder Daniel Ek and Hjalmar Nilsonne, the Swedish company operates preventive-health centers offering body scans, cardiovascular measurements, blood testing, and consultations with clinicians.

Its $700 million financing in July 2026 pushed its valuation to roughly four times the $1.7 billion figure associated with its 2025 round. Neko's valuation roughly quadrupled since its 2025 round, and we trace what each one is worth, then and now, in our report covering longevity.

The customer figures help explain that increase. According to Neko Health's financing announcement, more than 100,000 people had completed a scan in Sweden and the United Kingdom, while over 350,000 had joined its waiting list or registered for an examination.

The Financial Times also reported that Neko's existing clinics were profitable. The company plans to use its latest funding to expand into the United States, including new locations in New York.

Few longevity biotechnology companies can offer comparable evidence of consumer demand. However, Neko has yet to demonstrate that its complete screening program increases lifespan, even if earlier detection can lead to useful medical interventions.

Can Function Health really compete with Neko Health?

Function Health is a credible competitor to Neko Health, particularly for consumers who prefer regular laboratory testing and online health tracking over visiting specialized scanning clinics.

Founded in 2022, Function built a membership service around extensive blood testing, optional imaging, and AI-supported interpretation of health information.

In November 2025, Function announced a $298 million Series B at a $2.5 billion valuation, led by Redpoint Ventures. The company reported serving hundreds of thousands of members.

Private financing databases subsequently tracked additional investment in July 2026 at a valuation of approximately $2.94 billion, although that figure should be treated separately from valuations announced directly by the company.

Neko's physical clinics give it considerable control over the customer experience, including proprietary scanning equipment and in-person medical consultations. Function can potentially expand more quickly through laboratory partnerships without building the same infrastructure.

Those differences will influence the economics of both companies. Neko must open and operate facilities, while Function depends more heavily on laboratory networks, member retention, and the usefulness of its diagnostic information.

The biggest unanswered question is whether Function's extensive testing produces enough actionable medical value to keep customers paying. Large test panels can reveal genuine problems, but they can also produce ambiguous findings that require additional examinations.

Bar chart of where investors put their money in longevity, by category: Where did longevity investors put their money this past year? (Longevity Market, NewMarketPitch)

In our document detailing everything you need to know about longevity, you will always find fresh funding data, taken straight from our own verified funding database.

Is Oura actually a longevity company or just a wearable brand?

Oura is now one of the largest commercial companies associated with longevity, with revenue exceeding $900 million in fiscal 2025, but its main product remains health monitoring rather than any treatment that changes biological aging.

The Finnish-founded company sells smart rings that measure sleep, activity, heart rate, temperature, and other physiological indicators. Customers also pay for memberships that provide ongoing access to health insights.

According to financial information in Oura's September 2026 IPO filing, revenue increased from approximately $407 million in fiscal 2024 to $908 million in fiscal 2025. That is about 123% growth. Oura more than doubling revenue in a year is hard to miss; we look at who is growing the fastest in our report on longevity.

For the nine months ending June 2026, revenue reached approximately $1.21 billion, compared with $698 million in the equivalent previous period. Paid membership reached around five million.

The revenue mix is particularly interesting. Memberships generated approximately $159 million in fiscal 2025, or about 17% of total revenue. In the following nine-month reporting period, memberships accounted for approximately $241 million, nearly 20% of revenue.

Oura therefore has a recurring revenue business with millions of paying users, even though hardware still accounts for most sales. Its financial scale is already far beyond what most experimental longevity biotechnology startups generate.

Oura belongs in the broader preventive-health market, where understanding sleep and physiological patterns can be valuable without demonstrating direct lifespan extension.

Could Loyal become the first startup to sell a genuine longevity drug?

Loyal has one of the clearest routes toward commercializing a drug specifically intended to extend lifespan, although its treatments are being developed for dogs rather than humans.

Founded by Celine Halioua, Loyal develops veterinary medicines that target biological mechanisms associated with aging.

Its lead candidate, LOY-002, is a daily oral treatment for older dogs. The company is investigating whether improving metabolic health can delay age-related decline and help dogs live longer.

In February 2026, Loyal announced a $100 million Series C. The financing followed progress through the FDA Center for Veterinary Medicine's expanded conditional approval process.

Loyal has reported acceptance of the preliminary efficacy and target-animal safety components of its application. Manufacturing documentation remains an important outstanding requirement, and the drug has not yet received commercial approval.

The company is also conducting its STAY study to evaluate longer-term outcomes, including potential lifespan benefits.

Dogs have much shorter lifespans than humans, allowing researchers to study age-related outcomes and survival over more manageable periods. If LOY-002 eventually extends healthy canine lifespan, Loyal could provide an important precedent for developing and regulating medicines that target aging.

Table of longevity startups that shut down or struggled, and why: What broke these longevity startups, and how did they end? (Longevity Market, NewMarketPitch)

Learning from others' mistakes is the cheapest lesson there is. In our report covering the longevity market, we look at what broke startups before you, so you don't repeat it.

Which smaller longevity biotech startups deserve more attention?

Juvena Therapeutics, Junevity, Gameto, and Rejuvenate Bio are among the smaller longevity-related startups worth watching because they are pursuing specific medical problems where progress can be tested more directly.

Juvena Therapeutics develops regenerative protein medicines intended to restore tissue function. Its lead candidate, JUV-161, targets muscle degeneration and related disorders. The company raised $33.5 million in January 2026, with participation from Eli Lilly, and has advanced JUV-161 into Phase 1/2 development.

Junevity works on small interfering RNA therapies designed to change cellular programs associated with aging and metabolic dysfunction. Its lead candidate, JUN_01, targets conditions including type 2 diabetes and obesity. The company disclosed $20 million in cumulative seed funding in December 2025.

Gameto focuses on reproductive biology. Its Fertilo technology uses stem cell-derived ovarian support cells to improve egg maturation during fertility treatment. The company raised a $44 million Series C in August 2025 and has advanced clinical development.

Rejuvenate Bio is investigating gene therapies targeting age-related diseases, building on research involving both animal models and human therapeutic applications.

These startups are targeting muscle disease, metabolic dysfunction, fertility, and other identifiable conditions where researchers can measure outcomes without waiting decades to observe lifespan changes. A successful treatment for one condition, however, may have little effect on aging elsewhere in the body.

Startup Core technology Concrete milestone
Juvena Therapeutics Regenerative proteins JUV-161 Phase 1/2 development
Junevity RNA-based cellular reprogramming JUN_01 preclinical development
Gameto Stem cell-derived ovarian support cells Fertilo clinical development
Rejuvenate Bio Gene therapy Aging-related gene therapy programs
Juvenescence Age-related drug development $76M Series B-1 first close
Gero AI-driven aging therapeutics $17M Series B in June 2026
HexemBio Stem cell rejuvenation $10.4M seed round in April 2026
Reservoir Neuroscience Brain vascular aging therapies $3M seed extension in June 2026

Is cellular reprogramming the most promising longevity technology?

Cellular reprogramming is currently one of the strongest candidates for a major breakthrough in longevity medicine, judging by its experimental results and the amount of capital committed to developing it.

The basic idea is that some changes associated with cellular aging may be reversible. Researchers try to restore older cells toward healthier functional states by changing how their genes are expressed.

The investment pattern is difficult to ignore. Altos Labs received approximately $3 billion in initial commitments, NewLimit has attracted hundreds of millions, and Life Biosciences raised another $80 million to move its clinical program forward. Money piling into Altos, NewLimit and Life Biosciences shows where attention sits, and we track which technologies are gaining traction in our longevity market report.

However, these companies are testing different versions of the same broad scientific idea.

Altos investigates cellular resilience and several rejuvenation mechanisms. NewLimit uses epigenetic reprogramming, beginning with liver cells. Life Biosciences is testing gene delivery that activates specific reprogramming factors in damaged eye tissue.

Cellular reprogramming has to be controlled carefully because changing a cell's identity too much could interfere with its normal function or create serious safety problems. Researchers also need to deliver treatments to the right cells and regulate gene expression.

That helps explain why the first human trials are targeting individual organs and diseases. Eye disorders and liver conditions offer outcomes that can be measured more directly than whole-body rejuvenation.

Other approaches have struggled to convert promising biology into clinical results. Senolytic drugs, designed to eliminate senescent cells, produced exciting laboratory findings but have not consistently demonstrated clinical benefits.

Unity Biotechnology became a prominent example. Following clinical setbacks involving its UBX1325 retinal program, the company approved a restructuring in May 2025 and subsequently described the cessation of clinical development.

For now, reprogramming has the strongest combination of investor backing, scientific ambition, and emerging human testing. Its success will depend on whether those experiments produce meaningful benefits in patients.

Bar chart of the longevity market size year by year to 2036, with its growth rate: Where could the longevity market be in ten years? (Longevity Market, NewMarketPitch)

In our research about longevity companies, we always try to gather several sources and make estimates that make sense, so you can work with solid numbers.

Are longevity startups finally getting close to real medicines, and can biological age tests prove they work?

Longevity startups are now testing more experimental medicines in humans, but biological age measurements still cannot establish that those treatments extend lifespan.

Life Biosciences has administered ER-100 to patients with glaucoma. Retro Biosciences advanced an autophagy-focused medicine into early clinical development. Juvena is testing a regenerative protein therapy, while NewLimit is preparing to bring its first reprogramming medicine into human trials.

We can also look at companies further along in traditional drug development. BioAge Labs, which completed its IPO in 2024, advanced BGE-102, an NLRP3 inhibitor targeting inflammation-related conditions, into Phase 2 trials.

Insilico Medicine, publicly listed in Hong Kong since December 2025, moved its AI-discovered drug rentosertib into Phase 3 development for idiopathic pulmonary fibrosis in September 2026.

These programs show how longevity-related research can lead to medicines targeting specific diseases. However, treating an age-related condition does not necessarily slow aging throughout the body.

That creates a measurement problem. A lifespan study in humans could take decades, so researchers are developing biological age tests that might reveal treatment effects much sooner.

Epigenetic clocks use DNA methylation patterns to estimate biological age or aspects of aging-related risk. Other approaches combine proteins, metabolites, physiological measurements, and clinical indicators.

A 2026 study published in Nature Medicine examined how DNA methylation aging biomarkers respond to different interventions. It found that newer measures, including DunedinPACE and PCGrimAge, appeared particularly useful for evaluating biological responses.

The researchers also stressed that changes in these measures still need validation against meaningful clinical outcomes.

A treatment that reduces someone's estimated biological age by three years has not necessarily given that person three additional years of life. An intervention could change inflammatory markers used in an aging model without producing an equivalent improvement in long-term health.

For now, biological age tests can help researchers study treatments, but they remain an imperfect substitute for evidence that patients actually live longer or healthier lives.

What could stop today's biggest longevity startups from succeeding?

The biggest risk facing NewLimit, Altos Labs, Life Biosciences, and Retro Biosciences is straightforward: their experimental medicines could fail in clinical trials even after years of promising laboratory results.

Previous attempts at developing aging-related treatments show how difficult this can be.

Unity Biotechnology attracted substantial investment around senescent-cell biology before disappointing clinical results led to restructuring and the cessation of development programs.

BioAge Labs experienced another kind of setback. In 2024, it discontinued its azelaprag obesity program following safety concerns.

Cellular reprogramming adds complications of its own. Researchers have to control changes in cellular identity, avoid abnormal growth, and deliver treatments to the correct tissues. Gene therapies also face demanding manufacturing and regulatory requirements.

These challenges become especially important when companies reach multibillion-dollar valuations without approved products.

Altos can finance research across many different programs, but its budget cannot guarantee clinical success. NewLimit's valuation reflects expectations about future medicines rather than pharmaceutical revenue already being generated.

Commercial preventive-health startups face different problems. Neko Health has to expand its clinic network without losing operational efficiency or clinical quality. Function Health must convince customers that repeated testing remains useful enough to justify ongoing membership fees. Oura has to defend its position in a wearable market where competitors can develop similar monitoring features.

Map of longevity business models with company logos: How do longevity companies really make their money? (Longevity Market, NewMarketPitch)

If you build or invest in the longevity market, you need to know which business models pay off now and which ones are fading. That's why our market report about longevity companies has a whole section on it.

Which longevity startups are most likely to become major companies?

NewLimit, Life Biosciences, Retro Biosciences, Neko Health, and Altos Labs currently have the strongest claims to leadership, although each has reached a different stage of development.

NewLimit takes our top position among private longevity therapeutics startups because it has brought together substantial financing, increasingly specific experimental results, and a planned transition into clinical development. Putting NewLimit first among private therapeutics startups is a judgment call, and we weigh who the likely future winners are in our longevity market report.

Life Biosciences ranks especially highly because it has already treated humans with its experimental cellular-reprogramming therapy. Its evidence is still preliminary, but the company has made a transition that many competitors are working toward.

Retro Biosciences also deserves a leading position for moving an aging-related medicine into human testing. Its broader portfolio offers several potential routes toward useful treatments, although it also spreads development resources across different technologies.

Altos Labs has far more financial resources than most competitors. Still, we rank it below companies with more visible clinical progress because its research has yet to produce publicly disclosed human trial results.

Neko Health deserves a different kind of recognition. Its customer base, clinic network, and reported operating economics already support a substantial commercial business.

Our ranking places scientific advancement and strategic position ahead of valuation.

Rank Startup Strongest advantage Biggest unresolved question
1 NewLimit Financing and reprogramming platform Will its therapies work in humans?
2 Life Biosciences First-in-human reprogramming evidence Will early observations become proven efficacy?
3 Retro Biosciences Multiple therapeutic programs reaching development Can its medicines improve clinical outcomes?
4 Altos Labs Exceptional capital and research capabilities When will its research produce clinical candidates?
5 Neko Health Consumer demand and clinic economics Can it scale profitably and improve health outcomes?
6 Loyal Advanced veterinary regulatory strategy Will its drug extend healthy canine lifespan?
7 Function Health Membership adoption and diagnostic platform Will extensive testing deliver lasting clinical value?
8 Juvena Therapeutics Clinical regenerative biologics and Lilly relationship Can tissue restoration produce meaningful results?
9 Junevity Targeted RNA-based rejuvenation Will preclinical metabolic effects translate to patients?
10 Gameto Advanced reproductive biotechnology Can its technology become a widely adopted treatment?

Longevity: what are the top startups now?

NewLimit is our top longevity biotechnology startup today, followed closely by Life Biosciences and Retro Biosciences. Altos Labs remains the biggest research bet, while Neko Health leads our commercial preventive-health group.

NewLimit has attracted substantial financing while reporting concrete progress in epigenetic reprogramming. Life Biosciences has already treated human patients, giving it an important advantage in clinical evidence. Retro Biosciences has moved quickly into drug testing, and Altos continues to operate with an unusually large research budget.

Meanwhile, Neko Health, Function Health, and Oura have demonstrated that people are willing to spend money on preventive healthcare and health monitoring. Those businesses already serve real customers at a scale that experimental rejuvenation companies have yet to approach.

Still, none of the leading startups has established that its treatment meaningfully extends human lifespan.

We therefore favor NewLimit for long-term therapeutic potential, Life Biosciences for early human reprogramming evidence, and Neko Health for commercial execution. The next major change in this ranking will probably come from clinical results rather than another billion-dollar financing.

Google Trends curve of worldwide searches over five years for the longevity market: Now, more and more people are googling longevity (Longevity Market, NewMarketPitch)

In our document detailing everything you need to know about longevity, we don't want to repeat what boring consulting reports say. Instead, we show you the real and latest market signals that matter.

Our methodology

Determining which longevity startups actually lead the industry requires looking beyond valuations, high-profile investors, and ambitious promises about extending human life. We broke the question into five dimensions: scientific progress, clinical development, funding momentum, commercial traction, and the credibility of each company's route toward measurable health improvements.

For each dimension, we examined recent financing announcements, research updates, clinical trial registrations, regulatory disclosures, published scientific studies, and operating figures. We then compared the evidence across companies, giving greater weight to progress that could be independently documented and to businesses demonstrating strength across several dimensions. A successful financing alone carried less weight than financing accompanied by measurable research or clinical advancement.

We assessed therapeutic developers and preventive-health businesses using different standards. For biotechnology companies, we examined the progression from laboratory findings to candidate development, manufacturing readiness, human testing, and clinical outcomes. For commercial businesses, we focused on reported customer adoption, revenue, recurring memberships, operating economics, and expansion capacity. We kept these distinctions explicit when forming the overall ranking.

We also separated different levels of evidence. Early human safety observations were not treated as proof of therapeutic efficacy, preclinical rejuvenation results were not equated with lifespan extension, and changes in biological-age biomarkers were not assumed to translate into additional years of healthy life. Funding commitments, completed financing rounds, and externally tracked valuations were assessed according to what each figure actually represents.

Our comparisons draw on a combination of primary company disclosures and independent scientific or regulatory material. Key sources include NewLimit's Series C announcement, NewLimit's research progress report, Life Biosciences' first human ER-100 observations, the ER-100 clinical trial registration, Retro Biosciences' financing and development update, and the original Cell research on mesenchymal drift.

For commercial performance, we used Neko Health's financing and customer figures, Function Health's Series B announcement, Oura's SEC financial disclosures, and Loyal's financing and veterinary development update. Our assessment of scientific validation and development risks also draws on Nature Medicine's research on epigenetic aging biomarkers, randomized trial evidence on biological-age measurements, UNITY Biotechnology's SEC disclosures, and BioAge Labs' regulatory filings.

Finally, we aggregated these findings to identify which startups had the strongest combination of demonstrated achievements and credible future potential. The ranking is an editorial judgment built from comparative evidence, rather than a mechanical ordering by funding, valuation, or clinical stage. Our aim was to establish who is genuinely advancing the field, while distinguishing progress toward useful medical treatments from the much larger and still unproven ambition of extending human lifespan.

Timeline of the events that pushed the longevity market forward, with their impact: What pushed longevity forward, year after year? (Longevity Market, NewMarketPitch)

In our report covering the longevity market, we like to show you the big picture. We know your time is precious, so we make every page quick to read and packed with as much learning as possible per minute.